Board-Ready Research vs Market Research: A Practical Guide

Market research tells you what a market looks like. Board-ready research tells a board what to do about it. The two get conflated constantly, and the cost shows up in strategy papers that get sent back, investment committees that stall, and non-executives who lose confidence in the executive team. If you are trying to work out which one you actually need, or why the last piece of research you commissioned did not land in the boardroom, this guide is for you.

Key Executive Takeaways

• Market research describes a market; board-ready research supports a specific decision, names the risks, and stands up to challenge from non-executives, regulators, and auditors.
• Board-ready research must include primary evidence from the stakeholders whose behaviour determines whether the decision succeeds, not just secondary data and analyst reports.
• If you commission market research when the board needs decision-grade evidence, expect the paper to be returned, the decision to be deferred, and your credibility to take the hit.

What market research actually delivers

Market research is built to size, segment, and describe. It answers questions like: how big is the SME lending market in the North West, what share do the top five players hold, what are customers saying about digital onboarding, where is pricing moving. It is useful, often necessary, and relatively cheap to produce. Good market research is a foundation. It is not a decision.

The limits matter. Market research is usually backward-looking, aggregated, and silent on the specific counterparties, regulators, distributors, or clients whose behaviour will determine whether your plan works. It rarely surfaces the objections a serious challenger will raise. And it almost never contains the primary evidence that a board or an investment committee needs to sign off capital, enter a new segment, or approve an acquisition.

What board-ready research is

Board-ready research is commissioned against a specific decision. It starts from the question the board is being asked to approve, works backwards to the evidence required to answer it credibly, and gathers that evidence with the same rigour you would expect in a regulatory submission or an audit file.

In practice, that means four things:

1. A defined decision. Not a topic. "Should we acquire Firm X" or "should we launch product Y in segment Z by Q3" is a decision. "Understanding the wealth market" is not.
2. Primary stakeholder evidence. Direct input from the customers, intermediaries, regulators, employees, or counterparties whose behaviour drives the outcome. Attributable where possible, anonymised where necessary, but always traceable.
3. Named risks and assumptions. The paper must state what has to be true for the plan to work, and what the evidence says about each of those assumptions. Vague confidence is not evidence.
4. A view, tested against challenge. Board-ready research is not neutral. It reaches a conclusion and shows how that conclusion holds up against the strongest counter-arguments.

Where teams go wrong

The most common failure is bringing market research to a decision that needs board-ready evidence. The paper describes the opportunity in detail, cites third-party reports, and then makes an ask. A competent non-executive will spot the gap in thirty seconds: where is the evidence that the specific stakeholders in this plan will behave as assumed.

The second failure is over-commissioning. Not every question needs primary research. If you are refreshing a strategic view of a market you already operate in, market research is fine. Reserve board-ready research for decisions where the cost of being wrong is material: acquisitions, new market entry, product launches with regulatory implications, remediation programmes, and anything that will be scrutinised by the FCA, PRA, or an external auditor.

How to commission it well

Write the board question first. Circulate it to the chair or SID before you commission anything, and confirm it is the question they want answered. Then specify the stakeholders whose evidence is required, the assumptions that must be tested, and the standard of proof. Agree upfront how dissenting or inconvenient findings will be reported. If the research provider is willing to soften findings to keep you comfortable, you have the wrong provider.

The decision point

Before your next major paper goes to the board, ask one question: is this describing a market, or is this answering a decision. If it is the former, and the board is being asked to approve something, you are not ready. Commission the primary evidence, or defer the decision.

Frequently Asked Questions

When is market research enough?

When the decision is low-consequence, reversible, or when you are refreshing a view of a market you already understand. It is also enough as an input to a broader board-ready piece, provided it is not the only evidence.

How long does board-ready research take?

Typically four to eight weeks, depending on the number of stakeholders and the sensitivity of the topic. Rushing it usually means cutting the primary evidence, which is the part that gives it its weight.

Can internal teams produce board-ready research?

Sometimes. The risk is that internal teams struggle to gather candid stakeholder input, particularly from customers, regulators, and intermediaries who will not speak freely to the firm proposing the decision. Independence matters most where the findings might be uncomfortable.

What should a board-ready paper look like?

Short, decision-led, and traceable. The recommendation on page one, the evidence and assumptions behind it clearly set out, the risks named, and an appendix that shows the methodology and stakeholder base. If a non-executive cannot see how you got from evidence to conclusion, the paper is not ready.